Skip to main content
Pfizer's NSCLC candidate gets NICE recommendation
7/8/2019

The UK's National Institute for Health and Care Excellence has approved Pfizer's Vizimpro, or dacomitinib, as a first-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer with epidermal growth factor receptor mutation. NICE issued a guidance recommending the therapy for National Health Service use.

Full Story: